Results 161 to 170 of about 10,206 (212)
Some of the next articles are maybe not open access.
2015
Salmeterol xinafoate is a potent and a long-acting β2-adrenoceptor agonist. It is prescribed for the treatment of severe persistent asthma and chronic obstructive pulmonary disease. Different methods were used to prepare (R)-(-)-salmeterol such as: mixing a sample of 4-benzyloxy-3-hydroxymethyl-ω-bromoacetophenone with sodium lauryl sulfate and the ...
Manal M, Anwar +2 more
openaire +2 more sources
Salmeterol xinafoate is a potent and a long-acting β2-adrenoceptor agonist. It is prescribed for the treatment of severe persistent asthma and chronic obstructive pulmonary disease. Different methods were used to prepare (R)-(-)-salmeterol such as: mixing a sample of 4-benzyloxy-3-hydroxymethyl-ω-bromoacetophenone with sodium lauryl sulfate and the ...
Manal M, Anwar +2 more
openaire +2 more sources
European Respiratory Journal, 1994
Dizziness, together with hypotension and faintness, are well-known adverse drug reactions of salbutamol that have been related to its cardiovascular effects. However, we could find no published reference to vertigo in patients taking salmeterol, in the absence of cardiovascular alterations.
A, López-Guillen +4 more
openaire +2 more sources
Dizziness, together with hypotension and faintness, are well-known adverse drug reactions of salbutamol that have been related to its cardiovascular effects. However, we could find no published reference to vertigo in patients taking salmeterol, in the absence of cardiovascular alterations.
A, López-Guillen +4 more
openaire +2 more sources
Clinical Journal of Sport Medicine, 1996
To assess the effects of 50 micrograms of inhaled salmeterol on pulmonary function, selected physical capacities, and fine motor control in 16 nonasthmatic male cyclists and triathletes, mean age of 23.2 (SD = 3.5) years.Randomized double-blind placebo-controlled crossover trial.Human Physical Performance Laboratory, the University of Western Australia.
A R, Morton +4 more
openaire +2 more sources
To assess the effects of 50 micrograms of inhaled salmeterol on pulmonary function, selected physical capacities, and fine motor control in 16 nonasthmatic male cyclists and triathletes, mean age of 23.2 (SD = 3.5) years.Randomized double-blind placebo-controlled crossover trial.Human Physical Performance Laboratory, the University of Western Australia.
A R, Morton +4 more
openaire +2 more sources
Clinical Pharmacokinetics of Salmeterol
Clinical Pharmacokinetics, 2002Salmeterol is an inhaled long-acting selective beta(2)-adrenoceptor agonist that is commercially available as the xinafoate (1-hydroxy-2-naphthoic acid) salt of the racemic mixture of the two optical isomers, (R)- and (S)-, of salmeterol. It acts locally in the lung through action on beta2 receptors.
CAZZOLA M +2 more
openaire +3 more sources
The pharmacology of salmeterol
Life Sciences, 1993Salmeterol was developed to provide prolonged bronchodilatation to control nocturnal symptoms and improve maintenance therapy in asthmatic patients. Salmeterol is > 10,000 times more lipophilic than salbutamol and has greater affinity for the beta 2-adrenoceptor.
M, Johnson +7 more
openaire +2 more sources
Salmeterol/Fluticasone Propionate Combination
Drugs, 1999Current evidence suggests that addition of the long-acting beta2-agonist salmeterol to an inhaled corticosteroid in patients with persistent asthma symptoms provides greater clinical benefit than doubling the dosage of the inhaled corticosteroid. Fixed combination salmeterol/fluticasone propionate in 3 different fluticasone propionate dosage strengths ...
C M, Spencer, B, Jarvis
openaire +2 more sources
The pharmacology of salmeterol
Lung, 1990The pharmacology of salmeterol hydroxynaphthoate (SALM) has been investigated in respiratory tissues in vitro and in animal models in vivo. In guinea pig trachea and human bronchial smooth muscle, SALM was more potent than isoprenaline (ISO), salbutamol (SALB), and clenbuterol (CLEN).
openaire +2 more sources